<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047164</url>
  </required_header>
  <id_info>
    <org_study_id>020284</org_study_id>
    <secondary_id>02-C-0284</secondary_id>
    <secondary_id>NCI-5744</secondary_id>
    <secondary_id>CDR0000257563</secondary_id>
    <nct_id>NCT00047164</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy</brief_title>
  <official_title>A Pilot Study of Ipilimumab (MDX-CTLA4, MDX-010) in Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies such as anti-cytotoxic T-lymphocyte-associated antigen-4 can&#xD;
      locate cancer cells and either kill them or deliver cancer-killing substances to them without&#xD;
      harming normal cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying anti-cytotoxic T-lymphocyte-associated antigen-4&#xD;
      monoclonal antibody to see how well it works in treating patients with lymphoma or colon&#xD;
      cancer that has not responded to vaccine therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal&#xD;
           antibody in patients with follicular or mantle cell lymphoma, colon cancer, or prostate&#xD;
           cancer refractory to vaccine therapy. (part I) (prostate cancer and mantle cell lymphoma&#xD;
           closed to accrual as of 3/10/2005; colon cancer closed to accrual as of 9/28/05)&#xD;
&#xD;
        -  Determine the toxicity of this drug at escalating doses in patients with follicular&#xD;
           lymphoma. (part II)&#xD;
&#xD;
        -  Determine the toxicity of this drug at escalating doses in patients with non-Hodgkin's&#xD;
           lymphoma or Hodgkin's lymphoma. (part III)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the ability of this drug to increase tumor-specific T-cell responses in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the ability of this drug to produce clinical tumor response in these patients.&#xD;
&#xD;
        -  Determine the effect of this drug on suppressor T-cell populations (CD4+ and CD25+&#xD;
           cells) in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot, partial dose-escalation study.&#xD;
&#xD;
        -  Part I (patients with prostate or colon cancer or follicular or mantle cell lymphomas)&#xD;
           (prostate cancer and mantle cell lymphoma closed to accrual as of 3/10/2005; colon&#xD;
           cancer closed to accrual as of 9/28/05): Patients receive anti-cytotoxic&#xD;
           T-lymphocyte-associated antigen-4 monoclonal antibody (MDX-CTLA4) IV over 90 minutes on&#xD;
           day 1. Treatment repeats every 28 days for 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
        -  Part II (dose-escalation) (patients with follicular lymphomas only): Patients receive&#xD;
           MDX-CTLA4 as in part I. Treatment repeats every 21 days for up to 6 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of MDX-CTLA4 until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Part III (dose-escalation*) (patients with non-Hodgkin's or Hodgkin's lymphoma):&#xD;
           Patients receive MDX-CTLA4 as in part II.&#xD;
&#xD;
      NOTE: No dose-escalation for lymphoma patients who have previously been treated with an&#xD;
      allogeneic stem cell transplantation.&#xD;
&#xD;
      Patients are followed every other month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 89 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity after every 3 courses of treatment and every month for up to a year after completion of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-cell response after every 3 courses of treatment and every month for up to a year after completion of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">89</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer (closed to accrual as of 3/9/2005)&#xD;
&#xD;
               -  Prior therapy on protocol NCI-00-C-0137 or NCI-00-C-0154&#xD;
&#xD;
               -  Progressive disease (2 consecutively rising PSA levels, new bone scan lesion, or&#xD;
                  progression of soft tissue)&#xD;
&#xD;
               -  PSA at least 5 ng/mL&#xD;
&#xD;
               -  Progressive androgen-independent disease&#xD;
&#xD;
                    -  Disease progression at least 4 weeks after flutamide withdrawal OR&#xD;
&#xD;
                    -  Disease progression at least 6 weeks after bicalutamide or nilutamide&#xD;
                       withdrawal OR&#xD;
&#xD;
          -  Histologically confirmed follicular or mantle cell non-Hodgkin's lymphoma (mantle cell&#xD;
             lymphoma closed to accrual as of 3/9/2005)&#xD;
&#xD;
               -  Prior therapy on protocol NCI-00-C-0133, NCI-01-C-0169, or NCI-00-C-0050&#xD;
&#xD;
               -  Progressive disease after standard treatment&#xD;
&#xD;
               -  Relapsed disease OR&#xD;
&#xD;
          -  Histologically confirmed colon cancer (colon cancer closed to accrual as of 9/28/05)&#xD;
&#xD;
               -  Prior therapy on protocol NCI-99-C-0023&#xD;
&#xD;
               -  Progressive disease OR&#xD;
&#xD;
          -  Histologically confirmed non-Hodgkin's lymphoma or Hodgkin's lymphoma&#xD;
&#xD;
               -  Progressive disease after standard treatment&#xD;
&#xD;
               -  No curative therapy exists&#xD;
&#xD;
               -  Prior allogeneic stem cell transplantation from a matched sibling or matched&#xD;
                  unrelated donor for an aggressive lymphoma allowed&#xD;
&#xD;
                    -  Last infusion of allogeneic cells (either hematopoietic stem cells or donor&#xD;
                       lymphocytes) must have occurred &gt; 90 days prior to study enrollment&#xD;
&#xD;
          -  No other standard therapy available or refused such therapy&#xD;
&#xD;
          -  No symptomatic or rapidly progressive malignancy requiring therapy&#xD;
&#xD;
          -  No symptomatic CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC at least 2,500/mm^3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 50,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Hematocrit at least 30%&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 3.0 mg/dL (unless due to Gilbert's disease)&#xD;
&#xD;
          -  SGOT and SGPT no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Rheumatoid factor negative if history or evidence of arthritis&#xD;
&#xD;
          -  Anti-nuclear antibody (ANA) titer no greater than 1:80 if history or clinical signs or&#xD;
             symptoms of connective tissue disease&#xD;
&#xD;
          -  No prior or active autoimmune disease (e.g., uveitis, rheumatoid arthritis, lupus&#xD;
             erythematosus, autoimmune hemolytic anemia, ulcerative and hemorrhagic colitis,&#xD;
             endocrine disorders [e.g., thyroiditis, hyperthyroidism, hypothyroidism, autoimmune&#xD;
             hypophysitis/hypopituitarism, or adrenal insufficiency], sarcoid granuloma, myasthenia&#xD;
             gravis, polymyositis,or Guillain-Barre syndrome)&#xD;
&#xD;
          -  No positive antibody titers to autoimmune diseases&#xD;
&#xD;
               -  Rheumatoid factor positive allowed unless ANA titer is greater than 1:80 and&#xD;
                  there is a history of or clinical signs or symptoms of connective tissue disease&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except adequately treated squamous&#xD;
             cell or basal cell skin cancer, carcinoma in situ of the cervix, or superficial&#xD;
             bladder cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 months after study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior vaccine therapy&#xD;
&#xD;
          -  No prior anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody&#xD;
             (MDX-CTLA4) for patients in part I of study&#xD;
&#xD;
               -  Patients in part II of study may have had up to 4 prior treatments with MDX-CTLA4&#xD;
&#xD;
          -  No concurrent vaccine therapy&#xD;
&#xD;
          -  No concurrent infliximab&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No concurrent mercaptopurine, methotrexate, or cyclophosphamide&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior steroids&#xD;
&#xD;
          -  No concurrent systemic, inhaled, or topical steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Prior intervening therapy for prostate cancer, non-Hodgkin's lymphoma or colon cancer&#xD;
             allowed&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No other concurrent immunosuppressants (e.g., cyclosporine or its analog)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Janik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Metabolism Branch;MET</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <name_title>John Edward Janik</name_title>
    <organization>NCI - Metabolism Branch;MET</organization>
  </responsible_party>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

